SCEMBLIX: payments to doctors
Payments that named SCEMBLIX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.8M
- Providers
- 8,838
- Transactions
- 35,156
- Average per transaction
- $51
The per-transaction average — $51 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,838 providers the average total is $202, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $1,682,828 | 94.2% |
| Novartis Pharma AG | $103,950 | 5.8% |